Aimee Bence Lin

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion–Positive NSCLC

Caicun Zhou, Benjamin Solomon, Herbert H. Loong et al. · New England Journal of Medicine · 2023 · 213 citations · Full text

Medicine, Oncology, Pharmacology +14

Selpercatinib in Patients With <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Alexander Drilon, Vivek Subbiah, Oliver Gautschi et al. · Journal of Clinical Oncology · 2022 · 205 citations · Full text

Medicine, Oncology, Pharmacology +8

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

David S. Hong, Jeffrey R. Infante, Filip Jankú et al. · Journal of Clinical Oncology · 2016 · 160 citations

Medicine, Oncology, Pharmacology +17

Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen

Andrew J. Poole, V. Karuppiah, Annabelle Hartt et al. · Nature Communications · 2022 · 105 citations · Full text

Medicine, Cancer Biology, Oncology +17

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau et al. · Molecular Cancer Therapeutics · 2014 · 101 citations · Full text

Medicine, Cancer Biology, Oncology +13